Three different types of chimeric antigen receptor (CAR) T-cell therapies have been approved to treat refractory or relapsed large B-cell lymphoma. Many patients have side effects such as immune effector cell-associated neurotoxicity syndrome, hematotoxicity (also called immune effector cell-associated hemato-toxicity), neutropenia, anemia, and thrombocytopenia. Over half of patients require RBC or platelet transfusions after CAR T-cell infusions, but little is…
Copyright © 2024 John Wiley & Sons, Inc. All Rights Reserved.
Privacy Policy